The no-reflow phenomenon: Epidemiology, pathophysiology, and therapeutic approach

Reviews in Cardiovascular Medicine

Volumn 6, Issue 2, 2005, Pages 72-83

  Alfayoumi, Fadi ^a   Srinivasan, Venkatraman ^a   Geller, Mark ^a   Gradman, Alan ^a  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Myocardial infarction; Myocardial perfusion; No reflow

Indexed keywords

4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; ABCIXIMAB; ADENOSINE; CARIPORIDE; CD11B ANTIGEN; CD18 ANTIGEN; CD18 MONOCLONAL ANTIBODY; CONTRAST MEDIUM; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLUCOSE; GRANULOCYTE ANTIBODY; INSULIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; ISOSORBIDE DINITRATE; MONOCLONAL ANTIBODY; NICORANDIL; PADGEM PROTEIN; PEXELIZUMAB; PLACEBO; POTASSIUM; ROVELIZUMAB; SELECTIN; TENECTEPLASE; THROMBOCYTE ACTIVATING FACTOR; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VERAPAMIL;

ADJUVANT THERAPY; BLOOD CLOT LYSIS; BLOOD FLOW VELOCITY; CLINICAL TRIAL; CONTRAST ECHOCARDIOGRAPHY; CONTRAST ENHANCEMENT; CORONARY ARTERY BLOOD FLOW; CORONARY REPERFUSION; CORONARY STENT; DIAGNOSTIC ACCURACY; DRUG MECHANISM; EARLY DIAGNOSIS; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE PERFUSION; HEART PROTECTION; HUMAN; META ANALYSIS; MICROVASCULAR ISCHEMIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROGNOSIS; PROTECTIVE EQUIPMENT; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; RISK REDUCTION; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR PATENCY;

ADENOSINE; ANIMALS; ANTIBODIES, MONOCLONAL; ECHOCARDIOGRAPHY; HUMANS; MICROCIRCULATION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NICORANDIL; THROMBOLYTIC THERAPY; VASCULAR PATENCY; VASODILATOR AGENTS; VERAPAMIL;

EID: 21044437073     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis, a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992; 85:1699-1705.
2. Magno G, Ames A III, Chiang J, et al. 'No reflow' after cerebral ischemia. Lancet. 1967; 2:569-570.
3. Kloner RA, Ganote CE, Jennings RB, The 'no reflow' phenomenon after temporary coronary occlusion in dogs. J Clin Invest. 1974; 54:1496-1508.
4. Sakuma T, Leong-Poi H, Fisher NG, et al. Further insight into the 'no reflow' phenomenon after primary angioplasty in acute myocardial infarction: the role of microthromboemboli. J Am Soc Echocardiogr. 2003;16:15-21
5. TIMI Study Group. The thrombolysis in acute myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312:932-936.
6. Anderson JL, Karagounis LA, Califf RM. Meta-analysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes for acute myocardial infarction. Am J Cardiol. 1996:78:1-8.
7. The Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary angioplasty tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621-1628.
8. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall MI. Circulation. 1996;93:1993-1999.
9. Constantini CO, Stone GW, Mehran R, et al. Frequency, correlates and clinical implication of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition in AMI. J Am Coll Cardiol. 2004;44:305-312.
10. Ito H, Iwakura K, Oh H, et al. Temporal changes in myocardial perfusion patterns in patients with reperfused anterior wall myocardial infarction. Circulation. 1995;91:656-662.
11. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570-580.
12. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in dogs. Am J Pathol. 1983;111:98-111.
13. Siminiak T, Egdell RM, Gorman DJ, et al. Plasma-mediated neutrophil activation during acute myocardial infarction: role of platelet activating factor. Clin Sci. 1995;89:171-176.
14. Entman ML, Youker K, Shoji T, et al. Neutrophil induced oxidative injury of cardiac myocytes: a compartmented system requiring CD11b/CD18-ICAM-1 adherence. J Clin Invest. 1992;90:1335-1345.
15. Jolly SR, Kane WJ, Bailie MB, et al. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ Res. 1984;54:277-285.
16. Lefer DJ, Flynn DM, Buda AJ. Effects of a monoclonal antibody directed against P-selectin after myocardial ischemia and reperfusion. Am J Physiol. 1996;270:H88-H98.
17. Weyrich AS, Ma XL, Lefer DJ, et al. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest. 1993:91;2620-2629.
18. Yamazaki Y. Seko Y, Tamatani T. et al. Expression of intercellular adhesion molecule-1 in rat heart with ischemia/reperfusion and limitation of infarct size by treatment with antibodies against cell adhesion molecules. Am J Path. 1993;143:410-418.
19. Ma XL, Lefer DJ, Lefer AM, Rothelin R. Coronary endothelial and cardiac protective effect of intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation. 1992;86:937-946.
20. Aversano T, Zhou W, Nedelman M, et al. A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion. J Am Coll Cardiol. 1995;25:781-788.
21. Arai M, Lefer DJ, So T, et al. An anti-CD-18 antibody limits infarct size and preserves LV function in dogs with ischemia and 48 hr reperfusion. J Am Coll Cardiol. 1996;27:1278-1285.
22. Chatelain P, Latour JG, Tran D, et al. Neutrophil accumulation in experimental myocardial infarcts, relation with extent of injury and effects of reperfusion. Circulation 1987;75:1083-1090.
23. Tanaka M, Brooks SE, Richard VJ, et al. Effect of anti-CD 18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs. Circulation. 1993;87:526-535.
24. Baran KW, Nguyen M, Mckendall GR, et al. Double blinded, randomized trial of anti-CD 18 antibody in conjunction with recombinant t-PA for acute MI: limitation of myocardial infarction following thrombolysis in acute MI (LIMIT-AMI) study. Circulation. 2001;104: 2778-2783.
25. Faxon DP, Gibbons RJ, Chronos NAF, et al, and HALT-MI Investigators. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol. 2002;40:1199-1204.
26. Baxter GF. The neutrophil as a mediator of myocardial ischemia-reperfusion injury: time to move on. Bas Res Cardiol. 2002;97:268-275.
27. Villanueva FS. Myocardial contrast echo in acute myocardial infarction. Am J Cardiol. 2002;90:suppl 38J-47J.
28. van't Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial perfusion in patients treated with primary angioplasty for acute MI. Myocardial Blush Grade. Circulation. 1998;97:2302-2306.
29. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-130.
30. Hoffmann R, Haager P, Lepper W, et al. Relation of coronary flow pattern to myocardial blush grade in patients with first acute myocardial infarction. Heart. 2003; 89:1147-1151.
31. Hoffmann R, Haager P, Arning J, et al. Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute MI in predicting IV function. Am J Cardiol. 2003;92:1015-1019.
32. Feldman LJ, Coste P, Furber A, et al. Incomplete resolution of ST segment is a marker of transient microcirculatory dysfunction after stenting for acute myocardial infarction. Circulation. 2003;107:2684-2689.
33. Santoro GM, Valenti R, Buonamici P, et al. Relation between ST segment changes and myocardial perfusion evaluated by myocardial contrast echo in patients with acute myocardial infarction treated with direct angioplasty. Am J Cardiol. 1998;82:932-937.
34. Johanson P, Jernberg T, Gunnarsson G, et al. Prognostic value of ST-segment resolution - when and what to measure. Eur Heart J. 2003;24:337-345.
35. Kitagawa K, Sakuma H, Hirano T, et al. Acute myocardial infarction: myocardial viability assessment in patients early thereafter - comparison of contrast enhanced MR imaging with resting 201-T1 SPECT 1. Radiology 2003; 226:138-144.
36. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by MRI in patients with acute myocardial infarction. Circulation. 1998; 97:765-772.
37. Robert-Valla C, Boichot C, Zeller M, et al. Magnetic resonance imaging early after acute myocardial infarction. A visual analysis of myocardial perfusion based on a 17 segment model. Ann Cardiol Angeiol. 2003;52:7-14.
38. Iwakura K, Ito H, Takiuchi S, et al. Alteration in the coronary blood flow velocity pattern in patients with 'no reflow' and reperfused acute myocardial infarction. Circulation. 1996; 94:1269-1275.
39. Tsunoda T, Nakamura M, Wakatsuki T, et al. The pattern of alteration in flow velocity in the recanalized artery is related to left ventricular recovery in patients with acute infarction and successful direct angioplasty. J Am Coll Cardiol. 1998;32:338-344.
40. Wakatsuki T, Nakamura M, Tsunoda T, et al. Coronary flow velocity immediately after primary coronary stenting as a predictor of ventricular wall motion recovery in acute myocardial infarction. J Am Coll Cardiol. 2000;35: 1835-1841.
41. Yamamoto K, Ito H, Iwakura K, et al. Two different coronary blood flow velocity patterns in thrombolysis in myocardial infarction flow grade 2 in acute MI. J Am Coll Cardiol. 2002; 40:1755-1760.
42. Sabia PJ, Powers ER, Ragosta M, et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med. 1992; 372:1825-1831.
43. Lepper W, Hoffmann R, Kamp O, et al. Assessment of myocardial perfusion by intravenous myocardial contrast echo and coronary flow reserve after primary percutaneous transluminal angioplasty in patients with acute myocardial infarction. Circulation. 2000; 101:2368-2374.
44. Grill HP, Brinker JA, Taube JC, et al. Contrast echo mapping of collaterized myocardium in humans before and after angioplasty. J Am Coll Cardiol. 1990;16:1594-1600.
45. Swinburn MA, Lahiri A, Senior R, et al. Intravenous myocardial contrast echo predicts recovery of dysenergic myocardium early after acute myocardial infarction. J Am Coll Cardiol. 2001;38:19-25.
46. Kuersten B, Nahar T, Vannan MA. Methods of contrast administration for myocardial perfusion imaging: continuous infusion vs. Bolus infusion. Am J Cardiol. 2002;90:35J-37J.
47. Brochet E, Czitrom D, Karila-Cohen D, et al. Early changes in myocardial perfusion patterns after myocardial infarction: relation with contractile reserve and functional recovery. J Am Coll Cardiol. 1998;32:2011-2017.
48. Balcells E, Eric ER, Lepper W, et al. Detection of myocardial viability by contrast echocardiography in acute infarction predicts recovery of resting function and contractile reserve. J Am Coll Cardiol. 2003;41:827-833.
49. Adgey AA. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Eur Heart J. 1998; 19 (Suppl D): D10-D21.
50. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
51. Giri S, Mitchel JF, Hirst JA, et al. Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction. Am J Cardiol. 2000;86:269-274.
52. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observation from the TIMI 14 trial. Circulation. 2000;101:239-243.
53. Neumann FJ, Blastini R, Schmitt C, et al. Effect of Glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in myocardial infarction. Circulation. 1998;98:2695-2701.
54. Cronstein BN, Levin RI, Belanoff J, et al. Adenosine, an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest. 1986;78:760-770.
55. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effect of intracoronary adenosine as an adjunct to primary angioplasty in acute MI. Circulation 2000;101:2154-2159.
56. Assali AR, Sdringola S, Ghani M, et al. Intracoronary adenosine administered during PCI in acute MI and reduction of 'no reflow' phenomenon. Catheter Cardiovasc Interv. 2000; 51:27-31.
57. Kopecky SL, Aviles RJ, Bell MR, et al. A randomized double blinded placebo controlled, dose ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary PTCA. The ADMIRE (AmP579 delivery for myocardial infarction Reduction) study. Am Heart J. 2003;146:146-152.
58. Quintana M, Hjemdahl P, Sollevi A, et al. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complication (ATTACC) study. Eur J Clin Pharmacol. 2003;59:1-9.
59. Mahaffey KW, Puna JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy in acute myocardial infarction: the Acute Myocardial Infarction STudy of Adenosine. AMISTAD trial. J Am Coll Cardiol. 1999. 15;34:1711-1720.
60. Ross A, Gibbons R, Kloner RA, Marder VJ. The Acute Myocardial Infarction STudy of ADenosine. AMISTAD II. J Am Coll Cardiol. 2002. 39;Suppl A:338A.
61. Werner S, Lang K, Kuehnert H, Figulla H. Intracoronary verapamil for reversal of 'no reflow' during coronary angioplasty for acute MI. Catheter Cardiovasc Interv. 2002;57:444-451.
62. Brogden RN, Benfield P. Verapamil, a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs. 1996; 51:792-819.
63. Campbell CA, Kloner RA, Alker KJ, Braunwald E. Effect of verapamil on infarct size in dogs subjected to coronary artery occlusion with transient reperfusion. J Am Coll Cardiol. 1986;8:1169-1174.
64. Bonebrake FC, Bertha B, Folts JD. Verapamil combined with aspirin for inhibiting epinephrine stimulated platelet thrombus formation in stenosed canine coronary arteries. Coron Artery Dis. 1990;2:487-492.
65. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute MI. J Am Coll Card. 1997;30:1193-1199.
66. Pieper GM, Gross GJ. Anti free radical and neutrophile modulating properties of the nitro vasodilator nicorandil. Cardiovasc Drugs Ther. 1992;2:225-232.
67. Akai K, Wang Y, Sato K, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels, its dependency on vessel size and involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 1995;26: 541-547.
68. Tsubokawa A, Ueda K, Sakamoto H, et al. Effect of intracoronary nicorandil administration on preventing 'no reflow'/ slow flow during rotational atherectomy. Circ J. 2002;66:1119-1123.
69. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall MI. J Am Coll Cardiol. 1999; 33:654-660.
70. Sugimoto K, Ito H, Iwakura K et al. IV nicorandil in conjunction with coronary reperfusion is associated with better clinical and functional outcome in patients with AMI. Circ J. 2003; 67:295-300.
71. Ikeda N, Yasu T, Kubo N, et al. Nicorandil vs. isosorbid dinitrate as an adjunct treatment to direct balloon angioplasty in acute myocardial infarction. Heart. 2004;90:181-185.
72. Minamino T, Jiyoong K, Asakura M, et al. Rationale and design of a large-scale trial using nicorandil as an adjunct to percutaneous coronary intervention for STEMI: Japan working groups of acute MI for the reduction of necrotic damage by K-ATP channel opener. (J-WIND-KATP). Circ J. 2004;68:101-106.
73. Jung O, Albus U, Lang HJ, et al. Effect of acute and chronic treatment with the sodium hydrogen exchanger (NHI-I) inhibitor cariporide on myocardial infarction mass in rabbits with hypercholesteremia. Basic Clin Pharmacol Toxicol. 2004;95:24-30.
74. Rupprecht HJ, vom Dahl J, Terres W, et al. Cardioprotective effect of the Na (+) H (+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 2000;101:2902-2908.
75. Theroux P, Chaitman BR, Danchin N, et al. Inhibition of the sodium hydrogen exchanger (NHI-I) inhibitor with cariporide to prevent myocardial infarction in high risk ischemic situation. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) investigators. Circulation 2000; 102:3032-3038.
76. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of Pexelizumab as an adjunct to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in MI treated with thrombolytics (COMPLY) trial. Circulation 2003;108:1176-1183.
77. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab as an adjunct to primary PCI in acute MI: the COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Circulation 2003;108:1184-1190.
78. Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass. JAMA. 2004; 291:2319-2327.
79. Ceremuzynski L, Budaj A, Czepiel A, et al. Low dose glucose-insulin-potassium is ineffective in acute MI: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther. 1999;13:191-200.
80. Van Der Horst IC, Zijlstra F, van't Hof AW, et al. GIK infusion in patients treated with primary angioplasty for AMI. J Am Coll Cardiol. 2003;42:784-791.
81. Pache J, Kastrati A, Mehilli J, et al. The Reevaluation of Intensified Venous Metabolic Support for Acute Infarct Size Limitation (REVIVAL). Am Heart J. 2004;148:e3.
82. Stone GW, Webb J, Cox DA, et al. Primary angioplasty in acute myocardial infarction with distal protection of the microcirculation: principal results from the prospective, randomized EMERALD trial (abstract). J Am Coll Cardiol. 2004;43(5, suppl A):285A.
83. Yip H, Wu CJ, Chang HW, et al. Effect of the PercuSurge device on the integrity of microvasculature and clinical outcomes during PCI for AMI. Am J Cardiol. 2003;92:1331-1335.